Xiamen Amoytop Biotech Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Phase 2

Completed

Conditions: Breast Cancer
Non Small Cell Lung Cancer

Interventions: Drug: PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Drug: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Drug: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Drug: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

First Posted Date: 2013-12-09

Last Posted Date: 2018-07-17

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT02005458

Locations: 🇨🇳
Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, Fujian, China
🇨🇳
Shanghai Changzheng Hospital, Shanghai, China
🇨🇳
Shaaxi Provincial Tumor Hospital, Xi'an, Shaanxi, China

and more 9 locations

PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pegylated rhEPO
Drug: EPIAO®

First Posted Date: 2013-02-27

Last Posted Date: 2015-08-31

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT01800305

Locations: 🇨🇳
302 Military Hospital of China, Beijing, China

Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Phase 3

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Ypeginterferon alfa-2b
Drug: Pegasys

First Posted Date: 2013-01-03

Last Posted Date: 2015-08-31

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 820

Registration Number: NCT01760122

Locations: 🇨🇳
Beijing Youan Hospital, Capital Medical University, Beijing, China
🇨🇳
Xiangya Hospital, Central-south University, Changsha, China
🇨🇳
Xiangya Second Hospital, Central-south University, Changsha, China

and more 40 locations

Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

Phase 3

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ypeginterferon alfa-2b
Drug: Pegasys

First Posted Date: 2012-04-20

Last Posted Date: 2014-10-07

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 770

Registration Number: NCT01581398

Locations: 🇨🇳
85 Militay Hospital, Shanghai, China
🇨🇳
Huashan Hospital, Shanghai, China
🇨🇳
Xiangya Hospital, Central-south University, Changsha, China

and more 39 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Peginterferon alfa
Drug: Peginterferon alfa 2a
Drug: Peginterferon alfa-2a

First Posted Date: 2011-04-27

Last Posted Date: 2012-01-31

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 39

Registration Number: NCT01343186

Locations: 🇨🇳
302 Military Hospital of China, Beijing, China

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pegylated-Somatropin
Drug: YPEG-Somatropin

First Posted Date: 2011-04-20

Last Posted Date: 2013-02-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT01339182

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients

Phase 1

Completed

Conditions: Chemotherapy Patients

Interventions: Drug: YPEG-Filgrastim

First Posted Date: 2010-11-10

Last Posted Date: 2013-02-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT01238562

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT

Phase 4

Completed

Conditions: Mycoses

Interventions: Drug: rhG-CSF group
Drug: rhGM-CSF group
Drug: rhG-CSF+rhGM-CSF group

First Posted Date: 2010-11-02

Last Posted Date: 2014-11-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 206

Registration Number: NCT01232504

Locations: 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China

and more 2 locations

Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Ypeginterferon alfa-2b
Drug: Peginterferon alfa-2a

First Posted Date: 2010-06-14

Last Posted Date: 2013-02-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 205

Registration Number: NCT01143662

Locations: 🇨🇳
Tianjin Third Central Hospital, Tianjin, China
🇨🇳
First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China
🇨🇳
Tangdu Hospital, Fourth Military Medical University, Xian, China

and more 36 locations

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ypeginterferon alfa-2b
Drug: Peginterferon alfa-2a

First Posted Date: 2010-06-10

Last Posted Date: 2013-02-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 211

Registration Number: NCT01140997

Locations: 🇨🇳
302 Military Hospital, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
Xiangya Second Hospital, Central-south University, Changsha, China

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy